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1. Introduction  
Autoimmune thyroid diseases (AITDs) such as Hashimoto’s disease (HD) and 
Graves’disease (GD) are archetypes of organ-specific autoimmune disease (Davies et al., 
1988; Volpe, 1995). Hashimoto’s disease (HD), Hashimoto's thyroiditis (HT) or chronic 
autoimmune lymphocytic thyroiditis was first described by H. Hashimoto in 1912 as 
struma lymphomatosa (Hashimoto H.,1912). Histological and cytological features of HT 
include a dense thyroidal accumulation of lymphocytes, plasma cells and occasional 
multinuclear giant cells. The epithelial cells are enlarged, with a distinctive eosinophilic 
cytoplasm, owing to increased number of mitochondria. HD is characterized by the 
presence of thyroid autoantibodies to thyroglobulin (Tg) and to thyroid peroxidase (TPO). 
The autoantibodies present in this disorder were identified in 1956 by Roitt et al. (Roitt et 
al., 1956).  
HT is the most common underlying cause for hypothyroidism. It has been estimated that 
about 3–4% of the population suffers from HT. This disorder is most commonly found in 
middle-aged and elderly females, but it also occurs in other age groups (Canaris et al. 2000). 
HT is distributed throughout the world without racial and ethnic restriction.  
The severity of HT vary among patients. Most patients with HD maintain a lifetime 
euthyroid state without any medical treatment, whereas others become hypothyroid. The 
immunological differences that underlie differences in severity remain unclear. Various 
cytokines may play role in this process; thyroid autoantibodies are independently involved 
in the severity of HD (Ito et al., 2006). The increased oxidative stress and a deficiency of 
cellular antioxidative defense in HT patients may be related to the processes of development 
of hypothyroidism.   
In this view, to clarify the role of serum cytokines and antioxidant enzyme activities in 
different stages of disease we investigated three sub-groups of patients with autoimmune 
thyroiditis according to the thyroid function: group I —euthyroid subjects; group II—
hypothyroid subjects; and group III—subjects treated with Levothyroxine and healthy 
controls.  
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2. Genetic and environmental factors 
The interaction between internal (genetic) and external (environmental and endogenous) 
factors is required to initiate Hashimoto's disease. Environmental triggers of HT include 
high iodine intake, selenium deficiency, pollution, stress, bacterial and viral infections, 
cytokine therapy (Noel et al., 2002; Tomer & Davies, 1993; Bartalena et al., 2007). Probably 
puberty, pregnancy and menopause are factors contributing to disease. The role of dietary 
iodine is well defined in epidemiological studies and in animal models and seems to be the 
most significant environmental factor to induce thyroiditis. Environmental factors 
(particularly, iodine intake and infection) could cause insult of the thyrocyte followed by 
abnormal expression of major histocompatibility complex (MHC) class I and class II 
molecules, as well as changes to genes or gene products (such as MHC class III and 
costimulatory molecules) needed for the thyrocyte to become an antigen-presenting cell 
(APC). In this stage, a modulating role of sequence variants of human leukocyte antigen 
(HLA) class II molecules could become pivotal in binding and presenting thyroid antigenic 
peptides derived from Tg, TPO and TSHR (thyroid-stimulating hormone receptor) 
(Weetman, 2003). Selenium is other micronutrient involved in thyroid hormone metabolism, 
which exert various effects, while maintaining the cell reduction-oxidation balance (Beckett 
& Arthur, 2004; Duntas, 2009). Genetic variations in Tg, and probably in TSHR and other 
thyroid-specific genes, might be responsible for generating an autoimmune response. 
Genetic factors predominate, accounting for approximately 80% of the likelihood of 
developing AITDs, whereas at least 20% is due to environmental factors.   
3. Pathogenesis 
Several antibody and cell-mediated mechanisms contribute to thyroid injury in autoimmune 
hypothyroidism. In general, in case of Hashimoto’s thyroiditis, the expressions of death 
receptors such as CD95 and death receptor ligands such as CD95L and TRAIL in the thyroid 
tissue appear to be much higher compared to normal subjects. Also, the expression of 
positive effectors of apoptosis such as caspase 3 and 8, as well as Bax and Bak appear to be 
relatively high in thyroiditis samples as compared to controls. This expression pattern 
clearly supports enhanced apoptosis as the mechanism underlying the loss of thyrocytes in 
Hashimoto’s thyroiditis. There is significant expression of Fas/CD95 and its ligand in the 
thyrocytes who undergo apoptosis in Hashimoto’s thyroiditis. Cytokines appear to play a 
crucial role in the pathology of the disease by enhancing the expression of caspases and 
there by sensitizing cells to FAS mediated apoptosis (Weetman, 2004).  
3.1 B Cell response 
Three principal thyroid autoantigens mentioned above are involved in AITDs. These are 
TPO, Tg and the TSH receptor. TPO Abs appear involved in the tissue destructive processes 
associated with the hypothyroidism observed in Hashimoto's and atrophic thyroiditis. The 
appearance of TPO Abs usually precedes the development of thyroid dysfunction. Some 
studies suggest that TPO Abs may be cytotoxic to the thyroid (Chiovato et al., 1993; Guo et 
al., 1997). The pathologic role of Tg Abs remains unclear. TPO Abs and/or Tg Abs are 
frequently present in the sera of patients with AITDs (Doullay et all., 1991). However, 
occasionally patients with AITDs have negative thyroid autoantibody test results. 
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Longitudinal studies suggest that TPO Abs may be a risk factor for future thyroid 
dysfunction; changes in autoantibody concentrations often reflect a change in disease 
activity.  
TPO is a 110 kD membrane bound hemo-glycoprotein with a large extracellular domain, 
and a short transmembrane and intracellular domain. TPO is involved in thyroid hormone 
synthesis at the apical pole of the follicular cell. Several isoforms related to differential 
splicing of TPO RNA have been described. TPO molecules may also differ with respect to 
their three-dimensional structure, extent of glycosylation and heme binding. Most of the 
TPO molecules do not reach the apical membrane and are degraded intracellularly. TPO 
autoantibodies were initially described as anti-microsomal autoantibodies (AMA) since they 
were found to react with crude preparations of thyroid cell membranes. The microsomal 
antigen was later identified as TPO (Czarnocka et al., 1985). TPO Abs is the most sensitive 
test for detecting autoimmune thyroid disease (Mariotti et al., 1990). TPO Abs are typically 
the first abnormality to appear in the course of developing hypothyroidism secondary to 
Hashimoto’s thyroiditis. In fact, when TPO Abs are measured by a sensitive immunoassay,  
over 95% of subjects with Hashimoto’s thyroiditis have detectable levels of TPO Abs. 
Tg - the prothyroid globulin, is a high molecular weight (660 kDa) soluble glycoprotein 
made up of two identical subunits. Tg is present with a high degree of heterogeneity due to 
differences in post-translational modifications (glycosylation, iodination, sulfation etc). 
During the process of thyroid hormone synthesis and release, Tg is polymerized and 
degraded. Consequently, the immunologic structure of Tg is extremely complex. The 
heterogeneity of Tg Abs are restricted in patients with AITDs compared with other thyroid 
disorders. Tg Abs measurements do not appear to be a useful diagnostic test for AITDs in 
areas of iodide sufficiency (Ericsson et al., 1985; Nordyk et al., 1993). Tg Abs are found in 
less than 60% of patients with lymphocytic thyroiditis.  
Tg and TPO antibodies occur in very high concentration in patients with Hashimoto’s 
thyroiditis and primary myxedema. Both of the antibodies show partial restriction to the 
IgG1 and IgG4 subclass. Tg antibodies usually mediate Antibody mediated cytotoxicity 
(ADCC), where as TPO antibodies form terminal complement complexes within the thyroid 
gland. Cell mediated injury may be necessary for TPO antibodies to gain access to their 
antigen and become pathogenic. 
Thyroid stimulating antibodies (TS Abs) occurs in 10% to 20% of patients with autoimmune 
hypothyroidism (AH) but their effects are obscured by TSH-R-blocking antibodies and 
destructive processes.   
Karanikas at al. demonstrate that high TPO Abs titres correlate with increased frequencies of 
T cells producing cytokines, enhancing cellular cytotoxic immunity, e.g. Interferon Gamma 
(IFN-Ǆ) and Tumor necrosis factor -alpha (TNF-ǂ), reflecting high disease activity. The role 
of thyroid autoantibodies in different stage of Hashimoto’s disease remains unclear. 
(Karanikas at al., 2005). 
To clarify the prevalence of TPO Abs in different stages in Hashimoto’s thyroiditis we 
measured serum levels of TPO Abs in 128 out-patients with autoimmune thyroiditis from 
the Department of Internal Medicine, Stara Zagora University Hospital (Bulgaria), with HT 
and in 52 healthy controls. In all patients diagnosis had been made by enlarged thyroid 
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glands, elevated TPO Abs and/or typical hypoechogenicity of the thyroid in high-resolution 
sonography. In negative TPO Abs patients fine needle aspiration biopsy (FNAB) was 
performed and typical cytological features of autoimmune thyroiditis were found. Serum 
levels of TSH, free thyroxin (fT4) were estimated. Fasting samples of venous blood were 
collected in the morning between 8.00 and 10.00 h. Serum samples were routinely collected 
and stored frozen at -20 C until assayed. At the time of sampling, neither of the patients and 
control subjects had clinical signs or symptoms of intercurrent illness. TPO Abs were 
measured by ELISA, using commercially available kits (The Binding Site LTD, England). 
FT4 was measured by competitive immunoassay on the ACS180 (Chiron Diagnostics USA). 
TSH was measured by a third generation two-site chemiluminometric assay on the ACS180. 
The reference range was 11.5-22.7 pmol/l for fT4 and 0.35-5.5 IU/ml for TSH. Patients 
were divided into tree subgroups according to the thyroid function. Group I (n=40) involved 
subjects with normal thyroid function (TSH and fT4 within the normal range). Group II 
(n=17) included patients with hypothyroidism (high levels of TSH and low or normal serum 
levels of fT4). In group III (n=71) were enrolled subjects with hypothyroidism treated with 
Levothyroxine (LT4) in a dosage to maintain TSH and fT4 within the normal range. The 
medication of Levothyroxine (range: 50-200 g) was given in the fasting state. Fifty two 
healthy subjects were included as controls. Informed consent was obtained from all 
participants in the study according to the ethical guidelines of the Helsinki Declaration. The 
relevant clinical and biochemical data of all of patients studied and controls are summarized 
in Table 1.  
 
Variables Controls HT Range 
N 52 128  
Gender (M/F) 9/43 9/119  
Age (years) 44.6±1.8 47.0±1.2  
TSH (mIU/l)  1.3±0.8 1 14.4±4.3 1 0.35-5.5 
fT4 (pmol/l) 15.8±0.6 2 12.8±2.8 2 12-22 
TPO Abs (U/ml) 12,7±1,9 3 528±39,2 3 < 150 
TPO Abs Neg/Pos(%) 52/0 (0%) 4 35/93 (73%) 4  
Statistical significance: 1, 2, 3, 4 : p<0.05 
Table 1. Clinical features of controls and Hashimoto’s thyroiditis patients included in the 
study (mean±SEM). 
Statistical analysis was carried out using the Statistica 5.5 for Windows. The results were 
reported as means  SD (SE). Student’s t-test or non-parametric Mann Whitney U test were 
used to determine whether differences between means were significant. Correlations 
between the different parameters were calculated by linear regression analysis. P  0.05 was 
considered statistically significant. 
The clinical and biochemical data of subgroups of Hashimoto’s thyroiditis patients are 
presents in Table 2.  
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Characteristics 
 
Group I Group II Group III Range 
N 40 17 71  
Gender (M/F) 0/40 1/16 8/63  
Age (years) 48.8±1.8 47.6±3.5 46.2±1.7  
TSH (mIU/l)  2.4±1.3 1 18.6±4.8 1,2 3.7±2.6 2 0.35-5.5 
fT4 (pmol/l) 14.6±2.2 3 10.3±3.1 3,4 17.1±4.4 4 12-22 
TPO Abs (U/ml) 397±57 5,6 691±95 5 574±58 6 <150 
TPO Abs Neg/Pos(%) 16/24 (60%)7 1/16 (94%)7 18/53 (75%)  
Statistical significance: 1, 2, 3, 4, 5, 6, 7 : p<0.05 
Table 2. Baseline characteristics and TPO Abs levels in Hashimoto’s thyroiditis patients – 
euthyroid group (Group I), hypothyroid group (Group II) and group of patients treated 
with Levothyroxine (Group III) (mean±SEM). 
We found statistical significant differences of serum TPO Abs levels in sub-groups of 
patients with autoimmune thyroiditis compared to controls. Concentrations of TPO Abs in 
euthyroid group (397±57 U/ml) are lower in comparison with both hypothyroid group 
(691±95 U/ml)  and group of patients treated with levothyroxine (574±58 U/ml) (p=0.02; 
p=0.03 respectively). After treatment with thyroid hormones serum levels of TPO Abs 
declined without reached statistical significance. We found significantly higher TPO Abs (+) 
patients in hypothyroid group in comparison with euthyroid Hashimoto’s group (x2 =6.63, 
p=0.01).  Ito at al. also found significantly higher titers of TPO Abs in HT patients with overt 
hypothyroidism than in those with euthyroidism (Ito at al., 2006).  The same study showed 
the significant association of IFN-Ǆ gene polymorphisms with the severity of autoimmune 
thyroid diseases (Ito et al., 2006). In work of Schmidt et al. serum TPO Abs levels also 
declined on HT patients, but after a mean 50 months of treatment with levothyroxine 
(Schmidt et al., 2008). We may conclude that patients with euthyroid HT differ 
immunologically from patients with hypothyroid HT. 
3.2 T Cell response 
3.2.1 Cytokines and Th1/Th2 balance 
Cytokines are small glycoprotein chemical structures that act in paracrine and endocrine 
fashion as soluble signals between cells and play a pivotal role in the immune response. 
They are the hormonal messengers responsible for most of the biological effects in the 
immune system, such as cell-mediated immunity and allergic type responses. T 
lymphocytes are a major source of cytokines. A wide array of cytokines including 
interleukin (IL)-2, IFN-Ǆ, TNF-ǂ, IL-4, IL-6, IL-10, IL-12, IL-13 and IL-15 are produced by the 
lymphocytes with some variation between patients (Nilsson et al., 1998). There are two main 
subsets of T lymphocytes, distinguished by the presence of cell surface molecules known as 
CD4+ and cytotoxic T cells (CD8+).  T lymphocytes expressing CD4+ are also known as 
helper T cells, and these are regarded as being the most prolific cytokine producers. CD4+ T 
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helper lymphocytes play a key role in the pathogenesis of inflammatory and autoimmune 
diseases via the production of distinctive sets of cytokines (Druet et al., 1996). On the basis 
of their pattern of cytokine synthesis, CD4+ Th (helper) cells were originally classified into 
Th1 and Th2 lymphocytes, which are involved in cellular and humoral immune responses, 
respectively (Tato et al., 2006).  The cytokines produced are known as Th1-type cytokines 
and Th2-type cytokines. Type 1 helper T cells are characterized by the production of pro-
inflammatory cytokines like IFN-Ǆ, IL-2, IL-12, IL-15, IL-18 and TNF-beta. Th1 cells are 
involved in cell-mediated immunity. The cytokines produced by Th1 cells stimulate the 
phagocytosis and destruction of microbial pathogens. Type 2 helper T cells are characterized 
by the production of IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. Th2 cells are thought to play a 
role in allergy responses and facilitate humoral immune responses. Cytokines like IL-4 
generally stimulate the production of antibodies. Improved understanding of Th1 and Th2 
differentiation will improve our overall understanding of the immune system. Th1 and Th2 
lymphocyte subpopulations are with different in some cases even contradictory functions 
(Ajjan et al., 1996; Sterzl 1999). A third subset of CD4+ cells (Th3 lymphocytes) mainly 
synthesize transforming growth factor - beta (TGF-ǃ) and are considered as regulatory cells 
(Shevach, 2000). 
Disturbed mechanism of innate immunity, resulting from macrophage activation through 
innate immunity receptors may be the basis of pathologically high levels of cytokine 
production and activation (Boraschi D. & Dinarello C.A., 2006). Classical macrophage 
activation in response to microbial products has long been recognised and gives rise to 
potent effector macrophages (M1), which kill microorganisms and tumour cells and produce 
proinflammatory cytokines and chemokines (including IL-12, TNF-ǂ, IL-1, IL-6, IL-8). More 
recently, it has been shown that anti-inflammatory molecules, such as glucocorticoid 
hormones, IL-4, IL-13 and IL-10, are more than simple inhibitors of macrophage activation, 
in that they induce a distinct activation pathway (alternatively activated macrophages) 
(Gordon, 2003; Mosser, 2003). Alternative macrophage activation with IL-4 and IL-13 
induces M2 macrophages, which can regulate inflammatory responses and adaptive Th1 
immunity (Mantovani et al., 2002; Mantovani et al., 2004). Classically and alternatively 
activated (polarised) macrophages have been referred to as M1 and M2, in analogy with the 
Th1/Th2 dichotomy in T cell responses. M1 or M2 polarised macrophages differ in terms of 
receptor expression, cytokine and chemokine production, and effector function. Differential 
cytokine production characterises polarised macrophages. The M1 phenotype includes IL-12 
and TNF-ǂ, while M2 macrophages typically produce IL-10, the IL-1 receptor antagonist (IL-
1Ra) and the type II IL-1 receptor (IL-1RII). Differential production of chemokines, which 
attract Th1 versus Th2 or T regulatory cells, integrates M1 and M2 macrophages in circuits of 
amplification and regulation of polarised T cell responses. The microenvironment thus 
influences macrophage activation and their subsequent functions. In this light, genetic and 
environmental conditions that promote M1/Th1 polarisation and inhibit M2/Th2 regulatory 
activity may contribute to the establishment of a chronic inflammatory condition. This may 
develop into autoimmunity following triggering events (e.g., an infection or trauma) that 
would induce an autoimmune adaptive response, through mechanisms of molecular 
mimicry. 
IL-12 is a proinflammatory cytokine mainly produced by activated macrophages, dendritic 
cells, and granulocytes (Hsieh et al., 1993; Macatonia et al., 1993; Heufler et al., 1996). It acts 
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upon T, B, and natural killer (NK) lymphocytes, although it is best known for inducing the 
differentiation of CD4+ T lymphocytes from a Th0 to a Th1 phenotype (Trinchieri, 1993). IL-
12 is a heterodimer (p70) composed of a p40 subunit that is expressed predominantly on 
antigen-presenting cells and a p35 subunit that is present constitutively in numerous cells. 
Both subunits, have to be secreted by the same cell for production of a bioactive molecule. 
IL-12 binds to a specific plasma membrane receptor, ultimately resulting in transcription of 
the genes involved in prototypic Th1 responses, such as IFN-Ǆ. In light of its ability to 
stimulate Th1 responses, IL-12 has been invoked as a key cytokine in the pathogenesis of 
organ-specific autoimmune diseases, which are often mediated by cellular immunity 
(Trinchieri, 2003).  
IL-18 is related to the IL-1 family in terms of its structure, receptor family and signal 
transduction pathways (Fantuzzi & Dinarello, 1999). The production of bioactive IL-18 is a 
multistep process involving synthesis of the precursor, synthesis and activation of the 
cleaving enzyme caspase-1, maturation and extracellular transport (Dinarello, 1999; Gracie 
et al., 2003). Mainly produced by macrophages  and APC (Okamura H et al. 1995), IL-18 acts 
in synergy with IL-12 for Th1 differentiation (Kohno et al.,1997; Robinson et al., 1997; 
Micallef et al., 1996). It also exerts pro-inflammatory properties by inducing the production 
of IL-1beta, TNF-ǂ, chemokines, nitric oxide and prostaglandins (Puren et al., 1998; Olee et 
al., 1999). The pleiotropic activities of IL-18 suggest an important role of this cytokine in the 
triggering and polarization of the immune response (Liew FY., 2003). Activated 
macrophages and Kupffer cells were first described to produce high levels of IL-18 
(Okamura H. et al., 1995). IL-18 is also produced by dendritic and Langerhans cells (Brossart 
et al., 1998) and APC represent the major source of IL-18 production (Akita et al., 1997). Like 
IL-1beta, IL-18 exerts proinflammatory properties, but this cytokine is also related to IL-12 in 
view of its capacity to induce the production of Th1 cytokines and to enhance cell-mediated 
immune cytotoxicity. Indeed, enhanced production and activity of IL-18 appears to be at a 
fundamental level in autoimmune pathologies.  
IFN-Ǆ, also called immune or type II interferon is a pleiotropic cytokine involved in the 
regulation of nearly all phases of immune and inflammatory responses, including the 
activation, growth and differentiation of T-cells, B-cells, macrophages, NK cells and other 
cell types such as endothelial cells and fibroblasts. It enhances MHC expression on antigen-
presenting and IFN-- production is characteristic of Th1 differentiation (Romagnani, 1997). 
IFN-Ǆ enhances the cytotoxic activity of T cells, macrophages and natural killer cells and 
thus has antiproliferative effects. It also increases the production of antibodies in response to 
antigens administered simultaneously with alpha-interferon, possible by enhancing the 
antigen-presenting function of macrophages (Mitcham, 2005). IFN-Ǆ is produced by Th0-
cells, activated Th1-cells (CD4+) and cytotoxic T cells (CD8+), and by NK cells. Practically 
any antigen can cause the secretion of  IFN-Ǆ in one or other way, and it is enhanced by IL-2 
and IL-12 which induce the NK-cells, and Th cells to form IFN- Ǆ. B-lymphocytes need IL-1 
to produce IFN-Ǆ. During its secretion, IFN-Ǆ influences on the secreting cells as well as on 
the cells around through IFN- Ǆ - receptors. The first necessary step in the functioning of the 
IFN-Ǆ pathway is its interaction with receptors located on the surface of the cells. IFN-Ǆ 
stimulates the expression of class I and class II MHC molecules and co-stimulatory 
molecules on antigen presenting cells; promotes the differentiation of naive helper T cells 
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into Th1 cells; activates polymorphonuclear leukocytes (PMN) and cytotoxic T cells and 
increases the cytotoxicity of NK cells and suppresses humoral immunity. 
IL-6 is a multi-functional cytokine, produced by lymphoid and non-lymphoid cells of the 
body, having regulatory effects on the immune and the hemopoietic system and causing an 
acute-phase reaction (Heinrich et al., 1990). IL-6 together with IL-2, TNF-ǂ and other 
cytokines is an essential part of the accessory signal which is needed for the activation and 
the proliferation of antigen-stimulated T-lymphocytes. Interleukin-6 is especially important 
in the early stages of T-cell differentiation. In this phase, it reinforces the effect of IL-2 and 
promotes the differentiation of CD4 cells into T helper 2 cells (Janeway et al., 2001). It 
controls the growth and proliferation of early progenitor cells in the thymus and bone 
marrow and is later important in both T-cell and NK cell activation (Lee et al.; 1989). The 
molecular form of IL-6 responsible for T-cell activation is released by monocytes. It 
augments the early events of activation. (Heinrich et al., 1990; Van Snick, 1990) IL-6 also 
functions as the required second signal in both antigen- or mitogen-activated T-cells. (Clark 
& Shu, 1990) This protein holds a very important role in the life of NK cells. IL-6 provides 
support for continued development throughout the life of a natural killer cell (Van Snick, 
1990). Interleukin-6 is very important in the stimulation of differentiation and proliferation 
of B-cells. Its most noted effect is found in the induction of permanent differentiation of B-
cells into plasma cells, antibody producing cells (Nawata et al., 1989). IL-6 enhances the 
release of antibodies by acting as a growth factor for already differentiated plasma cells. It 
stimulates mostly the release of IgG and IgA antibodies from these cells. IL-6 induces 
increased production of antibodies in B-cells (Nawata et al., 1989). 
IL-10 is a small protein known as a cytokine that functions as an important regulator of the 
immune system.  Although IL-10 is known to have many different roles in the immune 
system, its two major activities include inhibition of cytokine production by macrophages 
and inhibition of the accessory functions of macrophages during T cell activation (Abbas et 
al., 1994). The effects of these actions cause IL-10 to play mainly an anti-inflammatory role in 
the immune system IL-10 is mainly produced by the Th2 subset of CD4+ helper cells.  
However, it is also produced by some activated B cells, some Th1 cells (in humans), 
activated macrophages, and some other cells.  Kinetics studies demonstrate that IL-10 is 
synthesized later than other immunoregulatory cytokines by activated T cells or monocytes.  
This data may reveal the regulatory role of IL-10 in later phases of the immune response 
(Delves et al., 1998).  Studies have shown IL-10 to be an immunosuppressive agent that 
inhibits the synthesis of several monocyte and Th1 cell-derived cytokines (IL-1, -2, -6, -8, -12, 
TNF-beta, INF-Ǆ). Moreover IL-10 has been demonstrated to down-regulate class II MHC 
expression thereby inhibiting the antigen-presenting capacity of monocytes. Like other 
cytokines interleukin-10 has many effects upon the functions of cells such as lymphocytes, 
monocytes, natural killer cells, and dendritic cells.  Specifically, IL-10 is a cytokine that 
regulates immune-mediated inflammation.  It appears to have two major functions: (1) to 
inhibit cytokine (i.e., TNF, IL-1, chemokine, and IL-12) production by macrophages and (2) 
to inhibit the accessory functions of macrophages in T cell activation.  IL-10 accomplishes 
the latter function through the reduced expression of MHC class II molecules and certain co-
stimulators (e.g., B7).   The cumulative effect of these functions acts to inhibit T cell-
mediated immune inflammation.  IL-10 also has stimulatory actions on B cells and may 
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function as a switching factor for the production of IgG4 in humans (homologous to IgG1 in 
mice) (Delves et al., 1998) 
TNF- ǂ is a pleiotropic inflammatory cytokine.  This cytokine possesses both growth 
stimulating properties and growth inhibitory processes, and it appears to have self 
regulatory properties as well. TNF-ǂ is produced by neutrophils, macrophages, activated T- 
and B-lymphocytes, NK-cells, lymphokine-activated killer cell, astrocytes, endothelial cells, 
smooth and muscle cells. TNF-ǂ has been implicated in the mediation of a number of 
diseases including septic shock syndrome, cachexia, AIDS and in pathogenesis of certain 
autoimmune diseases. TNF-ǂ production may play a key kinetic role by amplifying release 
of cytokines IL-1ǂ, IL-1ǃ, and IL-6 and thereby affecting the severity of a response (Amiot et 
al., 1997). TNF-ǂ participates in both inflammatory disorders of inflammatory and non 
inflammatory origin (Strieter al., 1993).   TNF-ǂ is an acute phase protein which initiates a 
cascade of cytokines and increases vascular permeability, thereby recruiting macrophage 
and neutrophils to a site of infection.   
IL-15 shares many activities exerted by IL-2 including the stimulation and expansion of T 
cells thymocytes, B cells and natural killer cells owing to the fact that the receptors for IL-2 
and IL-15 share the same ǃ and Ǆ subunits. At least in murine models, IL-15 unlike IL-2 fails 
to significantly activate the apoptotic pathways when stimulating T cells as well as other 
responding lineages, suggesting that IL-15 promotes the establishment of long-term 
memory T cells. IL-15 is produced by a variety of tissues, including skeletal muscle, kidney, 
placenta, hematopoietic stromal cells etc. IL-15 is expressed by a wide range of human 
tissues and cell lines, including skeletal muscle, placenta, and epithelial cell cultures (Tagaya 
et al., 1996). This cytokine induces T and B cell proliferation and it is essential for cell 
survival and for maintenance of long-lived memory cells (Perera et al., 1999; Oh et al., 2008). 
IL-15 is known to have noninflammatory actions because it can be detected in normal 
muscle tissue, where it is thought to have an anabolic activity and can modulate adipose 
tissue deposition (Quinn et al., 2009).  
TGF-ß1 belong to a family of multifunctional polypeptides and is produced by a wide 
variety of lymphoid and nonlymphoid cells. The TGF-ßs are involved in a variety of 
different biological processes, including tumorigenesis, fibrosis, hemopoiesis, and 
immunoregulation (Prud’homme & Piccirillo, 2000; Grande, 1997). Lymphoid cells mostly 
produce TGF-ß1, an isoform that is also found in large amounts in bones and platelets and in 
the serum (Letterio & Roberts 1998). The activation of TGF-ß1 may be mediated by 
macrophages in inflammatory sites (Wallick et al., 1990). Regarding the immunoregulating 
role of TGF-ß1, this is an immunosuppressive cytokine, as it inhibits T and B cell 
proliferation, natural killer cell cytotoxic activity, and the generation of T cell cytotoxicity 
(Rook et al., 1986; Lee et al. 1987). Furthermore, TGF-ß1 is able to inhibit both T helper type 1 
and T helper type 2 cytokine production and decreases the interferon- Ǆ -induced expression 
of HLA class II antigens (Czarniecki  et al., 1988). 
3.2.2 Cytokines and the thyroid 
Both CD4+ and CD8+ T-Cells occur in thyroid lymphocytic infiltrate with a preponderance 
of CD4+ cells. There is an increase in activated T Cells expressing markers like HLA-DR. 
Thyroid cells express MHC class-II molecules as well as other immunologically important 
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molecules and behaves as an APC. Expression of ICAM-1, LFA-3 and MHC class I 
molecules by thyrocytes is enhanced by IL-1, TNF-ǂ and IFN-Ǆ (Weetman, 2004). This 
response increases the ability of cytotoxic T cells to mediate lysis. Thyroid cell destruction is 
mediated by Fas dependent mechanisms (Weetman, 2004; Wu et al., 1994). Cytokines and 
other toxic molecules such as nitric oxide and reactive oxygen metabolites probably also 
contribute directly to cell mediated tissue injury (Weetman, 2011). (Fig. 1) 
 
Fig. 1. Interaction between thyroid cells and the immune system via cytokines. 
Humoral immunity exacerbates cell-mediated damage in a secondary fashion, both by direct 
complement fixations (TPO antibodies) and by ADCC (Chiovato et al., 1993). Complement 
attack initiated via the classic or alternative pathway, impairs the metabolic function of 
thyroid cells and induces them to secrete IL-1, IL-6, reactive oxygen metabolites and 
prostaglandin. All of these enhance the autoimmune response. 
As well as T and B cell, dendritic cells and monocyte/ macrophages accumulate in the 
thyroid. Presumably they play a major role as APC and capable of providing co-stimulatory 
signals. Thyroid cell-derived monocyte chemoattractant-I, produced after TNF-ǂ, IFN-Ǆ, or 
IL-1 stimulation, is likely to be responsible for the accumulation of monocytes, which are 
important source of cytokines ( Simons, 1998). Many cytokines are now known to be 
produced by thyroid cells especially after stimulation with IL-1, including IL-1, IL-6, IL-8, 
IL-12, IL-13 and IL-15 (Weetman et al. 1990; Weetman et al. 1992; Ajjan et al. 1997).  
Gene expression of IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IFN-Ǆ, 
TNF-ǂ and a number of chemokines have been shown in both GD and HT tissue samples 
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(Ajjan et al. 1996; Azmi et al. 1997; Ashhab et al., 1999). Generally, a mixed Th1 and Th2 
pattern has been found in the samples analysed, although some studies, using quantitative 
techniques, have shown a Th1 response in HT and a Th2 response in GD (Heuer et all. 1996). 
However, the analysis of mRNA can be misleading, as gene expression does not necessarily 
correlate with protein production. To address this issue, immunohistochemical methods 
have been applied which demonstrated cytokine protein production by a variety of cells in 
AITDs tissue in vivo. IFN-Ǆ was found in infiltrating lymphocytes, IL-1 in endothelial cells, 
whereas IL-1, IL-6 and TNF-ǂ were produced by thyroid follicular cells (TFC) (Ajjan et al. 
1996). 
Cytokine production by TFC in vitro can be stimulated by IL-1, IFN-Ǆ and TNF-ǂ, and this 
may be important in increasing the size and the activity of the infiltrate in vivo. Cytokines 
enhance the expression of adhesion molecules on TFC and can stimulate nitric oxide and 
prostaglandin production by these cells, which may further have a role in localising and 
augmenting the inflammatory reaction (Ajjan et al. 1996). 
MHC class I expression is upregulated on TFC by IFN-Ǆ and TNF-ǂ treatment in vitro, 
which may play a role in tissue destruction through T-cell-mediated cytotoxicity (Ajjan et 
all. 1996). IFN-Ǆ also enhances MHC class II expression on TFC in vitro, which may have a 
role in enhancing the proliferation of non-B-7-dependent T cells, but may also have a 
protective role as detailed below. 
Apoptosis seems to play a role in AITDs, in particular HT (Palazzo et al. 2000). Cytokines 
can upregulate proapoptotic genes and downregulate antiapoptotic genes on TFC 
predosposing these cells to apoptosis. 
TFC are resistant to complement-mediated cell lysis, an effect mediated in part by the 
expression of several protective proteins, which can be upregulated by cytokines (Ajjan et al. 
1996). IFN-Ǆ and TNF-ǂ treatment of TFC in vitro renders these cells resistant to cell-
mediated cytotoxicity, whereas TGF-ǃ1 inhibits T cell proliferation and thyroid autoantigen 
recognition (Ajjan et al. 1996). 
IL-1 and IL-6 enhance TFC proliferation in culture but can also have inhibitory effects if cells 
are stimulated with TSH, emphasising the complex interaction of these molecules in vivo. 
IFN-Ǆ and TNF-ǂ inhibit TFC growth and proliferation, without affecting cell viability 
(Ajjan et al. 1996). TPO gene expression and Tg production are decreased by cytokine 
treatment of TFC in vitro, which may affect iodine organification in vivo (Rasmussen et all. 
1994). IFN-Ǆ can also downregulate TSHR gene expression (Nishikawa et al., 1993).  
Levels of IL-5 are increased in GD and HT sera (Hidaka et all., 1998), whereas IL-6, IL-8 and 
IL-12 concentration is increased in GD sera compared with controls (Tamaru et al., 1999; 
Salvi et al., 2000). Increased serum levels of IFN-Ǆ, IL-4, IL-6, IL-10 and TNF-ǂ were found in 
GD compared with controls indicating a mixed Th1/Th2 response in this disease (Al-
Humaidi, 2000). In recent study Sieminska at al. found increased production of IL-6 in 
postmenopausal women with Hashimoto’s thyroiditis (Sieminska et al., 2010). On balance, 
the concept of a predominance of a Th1 and Th2 response, in HT and GD respectively, is 
almost certainly an over-simplification as features of cell-mediated and humoral immunity 
can be found in both diseases. Some authors considered HT as Th1 disease (Phenekos et al., 
2004; Colin et al., 2004), others found a mixed Th1 and Th2 pattern (Heuer et al., 1996; 
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Weetman A.P, 2004). Th1-associated cytokines have antagonistic and counterregulatory 
effects on the functions of Th2 type cells and vice versa (Mosmann & Sad, 1996; Elenkov & 
Chrousos, 1999). Cytokines can modulate Th1/Th2 cell differentiation via chromatin 
remodeling of Th cell loci (Murphy & Reiner, 2002, Morinobi et al., 2004; Spilianakis & 
Flavell, 2004). 
The role of cytokines in different stages of Hashimoto’s thyroiditis is not well established 
and their participation in processes leading to hypothyroidism remains contradictory. 
Relatively few studies are available on the role of IL-12 and IL-18 in autoimmune 
lymphocytic thyroiditis, either in patients with Hashimoto’s thyroiditis or in mice. IL-15 
mRNA was detected in the majority of thyroid tissue samples from patients with 
multinodular goiter, GD, and HT (Ajjan et al. 1996). Furthermore the expression of IL-15 was 
increased after stimulation of TFC cells with TSH, IL-1 or IFN-Ǆ, suggesting that these cells 
are a source of IL-15 in the thyroid.  
To provide the involvement of Th1 and Th2 lymphocyte subpopulations and to clarify the 
role of some cytokines in different stages of Hashimoto’s disease we investigated 128 out-
patients from the Department of Internal Medicine, Stara Zagora University Hospital 
(Bulgaria), with autoimmune thyroiditis. Fifty two healthy subjects were included as 
controls. In all patients diagnosis had been made by enlarged thyroid glands, elevated TPO 
Abs and/or typical hypoechogenicity of the thyroid in high-resolution sonography. In 
negative TPO Abs patients FNAB was performed and typical cytological features of 
autoimmune thyroiditis were found. Serum levels of TSH, free thyroxin (fT4) were 
estimated. Fasting samples of venous blood were collected in the morning between 8.00 and 
10.00 h. Serum samples were routinely collected and stored frozen at -20 C until assayed. At 
the time of sampling, neither of the patients and control subjects had clinical signs or 
symptoms of intercurrent illness. Concentrations of IL-12, IL-18, IFN-Ǆ, IL-10, IL-6, TNF-ǂ, 
IL-15 and TGF- ß1 in the serum samples of patients and controls were evaluated by ELISA, 
using commercially available kits (R&D Systems, Minneapolis, USA). Patients were divided 
into tree subgroups according to the thyroid function. Group I (n=40) involved subjects with 
normal thyroid function (TSH and fT4 within the normal range). Group II (n=17) included 
patients with hypothyroidism (high levels of TSH and low or normal serum levels of fT4). In 
group III (n=71) were enrolled subjects with hypothyroidism treated with Levothyroxine 
(LT4) in a dosage to maintain TSH and fT4 within the normal range. The medication of 
Levothyroxine (range: 50-200 g) was given in the fasting state. Informed consent was 
obtained from all participants in the study according to the ethical guidelines of the Helsinki 
Declaration. 
The relevant clinical and biochemical data of all of patients studied and controls are 
summarized in Table 1. and Table 2.  
The results obtained for cytokine levels in blood serum are shown in Table 3. 
IL-18 was significantly higher in all HT patients (p=0.02) and both group II (p=0.03) and 
group III (p=0.01) in comparison with controls. The mean serum IL-12 levels in patients with 
HT were significantly higher than those in control subjects (p=0.014). (Fig.2) The serum IL-
12 levels were also higher in sub-groups in patients, statistically significant in group I and 
group III (p=0.015 and p=0.036 respectively) in comparison with controls. (Fig.3) 
Concentrations of IL-10 in sub-groups of patients - I and II tended to be lower in comparison 
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with controls. IL-15 was significantly lower in group II in comparison with controls (p<0.05). 
Serum concentrations of TGF- ß1 were not statistically different in sub-groups of patients 
and controls, but in all sub-groups of HT patients levels tended to be lower than in controls. 
 
Fig. 2. IL-18 serum levels in controls, in all patients with Hashimoto’s thyroiditis (HT), in 
euthyroid group (Gr. I), hypothyroid group (Gr. II) and group of patients treated with 
Levothyroxine (Gr. III). Data are presented as mean ± SEM. 
The relevant clinical and biochemical data of all of patients studied and controls are 
summarized in Table 1. and Table 2. The results obtained for cytokine levels in blood serum 
are shown in Table 3. 
 
Variables Controls HT Group I Group II Group III 
IL-10 0.77 ±  0.23 1.34±0.89 0.41±0.17 0.51±0.23 1.85±1.38 
IL-15 2.06±0.24 1 1.48±0.11 1.67±0.21 2 0.62±0.40 1,2 1.56±0.12 
IL-18 158.67±13.14 3,4,5 195.80±10.64 4 154.69±9.84 6,7 253.18±46.513,6 202.23±13.26 5,7 
TGF-ǃ1 25874,1±2894 18742±737 18967±1151 19830±2516 18305±1011 
TNF-ǂ 10.99±0.60 10.27±0.45 10.54±0.53 11.18±0.97 9.35±0.85 
IL-12 67.99±9.85 8,9,10 93.48±7.05 8 103.73±14.409 9 83.41±14.0 90.48±8.19 10 
IFN-Ǆ 1.79±0.11 11 1.61±0.72 1.68±0.12 1.56±0.29 11 1.58±0.09 
IL-6 1.47±0.29 2.22±0.36 1.79±0.50 3.96±1.30 1.71±0.29 
Statistical significance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11: p<0.05 
Table 3. Cytokine concentrations (pg/ml) in all Hashimoto’s thyroiditis patients and in 
particular groups of patients: euthyroid group (Group I), hypothyroid group (Group II) and 
group of patients treated with Levothyroxine (Group III) and controls (mean±SEM). 
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To further analyze the balance of immune regulation (Th1/Th2 balance) in individuals, the 
ratio between IL-12 and IL-6 was calculated. In comparison to control subjects, a clear bias 
towards Th1-dominated immune reactivity was found in group I - euthyroid Hashimoto’s 
patients (p=0.018). 
We found statistically significant lower serum levels of TGF-ß1 in TPO Abs (+) patients 
(17802±876 pg/ml) in comparison with TPO Abs (-) patients (21200±1291 pg/ml)  (p=0.018, 
Mann Whitney U test).  
An advantage of investigating serum cytokine levels in ATD is the ability to analyse 
cytokine profile early in the disease process, when the immune response is presumably 
more specific. However, serum cytokine levels may not reflect the intrathyroidal cytokine 
profile as levels of some cytokines may be very low in the periphery (falling below the 
detection sensitivity of the assay), despite high intrathyroidal concentrations.   
 
Fig. 3. IL-12 serum levels in controls, in all patients with Hashimoto’s thyroiditis (HT), in 
euthyroid group (Gr. I), hypothyroid group (Gr. II) and group of patients treated with 
Levothyroxine (Gr. III). Data are presented as mean ± SEM. 
Our results demonstrate that serum IL-12 levels were increased in all sub-groups in patients 
independently of functional state of the disease. The ratio between IL-12 and IL-6 
demonstrate a clear bias towards Th1-dominated immune reactivity  in group of euthyroid 
Hashimoto’s patients  in comparison to control subjects. In our previous work we found 
significantly increased serum levels of IL-12 in patients suffering from both GD and HT, 
which suggests that IL-12 might affect the immune response in both GD and HT (Halacheva 
et al., 2005). The results shown in the existing research carried out so far on IL-12 serum 
levels in GD and HT are contradictory. Phenekos et al. have shown that IL-12 serum 
concentrations were significantly higher than those in normal controls in HT patients but 
were not increased in patients suffering from GD (Phenekos et al., 2004). During iodine-
induced autoimmune (lymphocytic) thyroiditis in NOD mouse IL-12 is produced in the 
thyroid gland early and throughout the course of the disease (Bonita et al., 2003). Kimura at 
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al. have shown that the local production of IL-12 in the thyroid enhances the expression of 
sodium-iodide symporter and inhibits thyroid hormonogenesis downstream of the 
organification, thus inducing primary hypothyroidism; and the disease promoting effect of 
IL-12 was independent of of interferon-Ǆ (Kimura et al., 2005). On the basis of our results 
and data from experimental mouse models we may conclude that the effect of IL-12 on the 
initiation and regulation of immune responses and also on thyroid function is crucial in 
Hashimoto’s thyroiditis.  
We found that serum levels of IL-18 were significantly higher in HT; particularly in patients 
with severe disease and no change significantly after treatment with Levothyroxine in 
comparison with controls. Concentrations of IL-10 in sub-groups of patients tended to be 
lower in comparison with controls. Phenekos et al. demonstrated significantly increased IL-
18 serum levels in HT patients than those in normal controls and in patients suffering from 
GD and toxic nodular goiter (Phenekos et al., 2004). IL-18 expression was increased in the 
thyroid tissues of HT compared with control thyroid tissues in canine model and in humans 
(Choi et al., 2006, Liu et al., 2010). IL-18 acts in synergy with IL-12 for Th1 differentiation 
induce the production of Th1 cytokines and inhance cell-mediated cytotoxicity (Lebel-Binay 
et al., 2000).; Increased serum levels of IL-18 particularly in patients with severe disease and 
no change significantly after treatment with Levothyroxine suggest an altered 
immunological status in severe hypothyroid stage of the disease and during Levothyroxine 
replacement remained unchanged. Mazziotti et al. found different expression of IL-4 in 
CD4+ in hypothyroid and euthyroid patients with HT (Mazziotti et al., 2003). Taking 
together our and these results suggest a different immunological status for euthyroid and 
hypothyroid HT patients and the interaction between IL-12 and IL-18 may be related to 
development of thyroid destruction. 
Our results indicate lower serum levels of IL-15 in hypothyroid HT patients. Treatment with 
Levothyroxine increases serum levels of IL-15. In study of Ajjan at al. IL-15 was detected in 
all HT samples, and the expression was increased after stimulation of thyroid follicular cells 
with TSH, but all patients had been treated with Levothyroxine before surgery (Ajjan et al., 
1997). IL-15 expression has been detected in numerous tissues, many of which are not sites 
of immune responses (Fehniger & Caligiuri, 2008). Accordingly we may suppose that 
decreased serum levels of IL-15 in hypothyroid HT may be related to the process of thyroid 
apoptosis and hypometabolism of all tissues.  
TGF-ß1 regulate proliferation of follicule cells of the thyroid in many experiments in vitro. It 
has been proved that TGF- ß1 is an immunosuppressive cytokine, as it inhibits T and B cell 
proliferation, natural killer cell cytotoxic activity, and the generation of T cell cytotoxicity 
(Prud’homme & Piccirillo, 2000). In our work serum levels of TGF-ß1 are not statistically 
different in sub-groups of patients compared to controls, but in all HT patients they tended 
to be lower in comparison with controls. Our findings of significantly lower serum levels of 
TGF-ß1 in TPO Abs (+) patients than TPO Abs (-) suggest that TGF-ß1 may contribute to the 
severity of autoimmune thyroiditis.  Akinci et al. found lower levels of TGF- ß1 in 
hypothyroid HT patients when compared with control cases and their levels remained 
unchanged after Levothyroxine replacement (Akinci et al., 2008). Vural at al. also measured 
decreased plasma TGF-ß1 concentrations in HT patients in comparison with controls (Vural 
at al., 2009). On the basis of our and these data we suppose that autoimmunity may have 
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been triggered as a result of decreased immunosuppressive effect induced by depressed 
TGF- ß1 levels in patients with HT. 
We may summarize that Th1 pattern of immune response characteristic of cellular 
immunity is dominant in HT and sub-groups of patients have a different immunological 
status which contribute to development of hypothyroidism. 
3.3 Oxidative stress and antioxidant protection in Hashimoto’s thyroiditis 
3.3.1 Generation of reactive oxygen metabolites and antioxidant enzymes 
Molecular oxygen gives rise to dangerous reactive metabolites upon reduction to water 
(Fridovich, 1978). The term "free radical" covers any atom or molecule that contains one or 
more unpaired electrons (Halliwell 1991). Some of the reactive oxygen species (ROS) are free 
radicals, such as superoxide, nitric oxide and hydroxyl radical, whereas hydrogen peroxide 
(H2O2) is reactive and important, but not a free radical. Therefore, it is appropriate to speak 
of reactive oxygen species. ROS are continuously formed in the mitochondrial respiratory 
chain, via the cyclo-oxygenase pathway and by cellular enzymes, such as xanthine oxidase, 
NADPH oxidase and cytochrome P450 oxidase (Gadjeva et al., 2000). The main intracellular 
source of ROS is mitochondria. 
A typical feature of free radical reactions is that they proceed as chain reactions, amplifying 
the damage of the initial event. ROS cause cell injury by reacting with proteins, lipids, and 
DNA (De Zwart et al., 1999), but they are also an essential part of normal cellular 
physiology, such as signal transduction. Oxidative reactions occur in living organisms 
under physiological conditions. ROS and free radicals are essential for numerous metabolic 
processes. Under physiological conditions, there is a balance between the production and 
detoxification of ROS. However, any internal or external pathological factor may disrupt 
this balance, leading to conditions referred to as oxidative stress. Reactive oxygen species – 
О2-, OH-, H2O2 and NO when being in excess cause oxidative damage to molecules. Indeed, 
oxidative stress plays a significant role in the pathogenesis of several diseases. Excess H2O2 
has been reported to induce oxidative damage to membrane lipids, proteins and DNA that 
may result in cell death by necrosis or apoptosis. The levels of lipid peroxidation products 
(malondialdehyde – MDA) in plasma are widely used in practice as an indicator of free 
radical damages.  
Detoxification of ROS is one of the prerequisites of aerobic life, and hence an elaborate 
antioxidant system has evolved. Antioxidants are agents that scavenge ROS, prevent their 
formation, or repair the damage they cause (De Zwart et al., 1999). This complex system 
consists of antioxidant enzymes (superoxide dismutases, catalase, glutathione peroxidase) 
and other substrates. Of the antioxidant enzymes superoxide dismutases (SOD) catalyse the 
conversion of two superoxide molecules to hydrogen peroxide and oxygen, and hydrogen 
peroxide is mainly eliminated by catalase (CAT) and glutathione peroxidase (GPX). 
SOD is an endogenously produced intracellular enzyme present in essentially every cell in 
the body. Cellular SOD is actually represented by a group of metalloenzymes with various 
prosthetic groups. The prevalent enzyme is cupro-zinc (CuZn) SOD, which is a stable 
dimeric protein. 
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Catalase is a protein enzyme present in most aerobic cells in animal tissues. Catalase is 
present in all body organs being especially, concentrated in the liver and erythrocytes. The 
brain, heart, skeletal muscle contains only low amounts. 
Glutathione peroxidase is a selenium-dependent enzyme, which decomposes H2O2 and 
various hydro- and lipid peroxides. (Kinnula et al. 1995). The classical form of GPX is 
cellular and dispersed throughout the cytoplasm, but GPX activity is also found in 
mitochondria. GPX is considered more important in physiologic conditions (reviewed by 
Kinnula et al., 1995). Selenium is essential for the protein synthesis and enzymatic activity of 
GPX. 
SOD is considered fundamental in the process of eliminating ROS by reducing (adding an 
electron to) superoxide to form H2O2. Catalase and the selenium-dependent glutathione 
peroxidase are responsible for reducing H2O2 to H2O. Catalase and glutathione peroxidase 
seek out hydrogen peroxide and convert it to water and diatomic oxygen. An increase in the 
production of SOD without a subsequent elevation of catalase or glutathione peroxidase 
leads to the accumulation of hydrogen peroxide, which gets converted into the hydroxyl 
radical. 
The respective enzymes that interact with superoxide and H2O2 are tightly regulated through a 
feedback system. Excessive superoxide inhibits glutathione peroxidase and catalase to 
modulate the equation from H2O2 to H2O. Likewise, increased H2O2 slowly inactivates CuZn-
SOD. Meanwhile, catalases and glutathione peroxidase, by reducing H2O2, conserve SOD; and 
SOD, by reducing superoxide, conserves catalases and glutathione peroxidase. Through this 
feedback system, steady low levels of SOD, glutathione peroxidase, and catalase, as well as 
superoxide and H2O2 are maintained, which keeps the entire system in a fully functioning 
state (Fig.4). (Gadjeva et al., 2000; Al-Gubory K et al.; 2010). 
 
Fig. 4. Schematic representation of the pathways producing reactive oxygen species (ROS) 
and key cellular antioxidant enzymatic systems controlling ROS production.  
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3.3.2 Oxidative stress and antioxidant protection in Hashimoto’s thyroiditis 
In the thyroid hydrogene peroxide is necessary for thyroid hormonogenesis acting at 
different steps of the process. Excess H2O2 has been reported to induce oxidative damage to 
membrane lipids, proteins and DNA that may result in cell death by necrosis or apoptosis. 
The levels of lipid peroxidation products (malondialdehyde – MDA) in plasma are widely 
used in practice as an indicator of free radical damages. To prevent the damages caused by 
the ROS, multiple defense systems, collectively called antioxidants, are present in human 
serum, erythrocytes as well in the tissues. The presence of following antioxidative enzymes 
in the thyroid gland has been documented: superoxide dismutase, catalase  and glutathione 
peroxidase. GPX and TR (thioredoxin reductase) are selenoenzymes capable of modifying 
cell function by acting as antioxidants.  
In the thyroid, ROS and free radicals are constantly formed and participate in 
physiological and pathological processes in the gland. For example, H2O2 is necessary for 
thyroid hormonogenesis (Nunez & Pommier, 1982; Fayadat et al., 1999). But an in vitro 
experimental study H2O2 has been found to influence the process of cell death (Riou et al., 
1998). 
Cells have developed a comprehensive set of antioxidant defense mechanisms to limit the 
action of ROS. SOD catalyse the conversion of two superoxide molecules to H2O2 and 
oxygen. CAT and GPX mainly eliminate H2O2, as primary participants in the most 
important antioxidant enzyme pathways. The involvement of hyperthyroidism due to 
Graves’ disease in lipid peroxidation and antioxidant enzyme activities has been studied 
(Komosinska-Vassev et al., 2000; Gerenova & Gadjeva, 1996). The papers concerninig the 
influence of hypothyroidism have shown that this condition results in complex effects such 
as the augmentation of SOD and GPX activities and significant decrease of the CAT activity 
in rat liver mitochondria in experimental work (Das & Chainy, 2001) and augmentation of 
oxidative stress and disturbance of antioxidant defense in humans (Erdamar et al.,2008). The 
complex regulation of ROS generation and free radical-scavenging systems activity in 
patients with Hashimoto’s thyroiditis in different stages of disease activity has not been 
studied. The study of Hashimoto’s thyroiditis is plagued by the difficulties in examining a 
disease that progresses over long periods of time (Davies & Amino, 1993; Dayan & Daniels, 
1996). 
In our previous study we investigated the possible induction of oxidative stress and changes 
in antioxidant enzyme activities in Hashimoto’s thyroiditis and compared these parameters 
in different subgroups of patients (Gerenova & Gadjeva, 2007). For this purpose seventy-one 
patients with autoimmune thyroiditis and 30 healthy controls were studied. Patients were 
divided into tree subgroups according to the thyroid function: group I – euthyroid subjects; 
group II – hypothyroid subjects; group III – subjects with hypothyroidism treated with 
Levothyroxine (LT4) to maintain TSH and fT4 winthin the normal range. The levels of of 
lipid peroxidation products - MDA in the plasma, and the antioxidant defences such as 
SOD, CAT and GPX activities in erythrocytes were measured.  
Between June 2003 and April 2005 seventy-one out-patients (4 males, 67 females, of mean 
age 45.913.1 years) from the Department of Internal Medicine, Stara Zagora University 
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Hospital (Bulgaria) with Hashimoto’s thyroiditis were recruited and investigated in 
prospective study. From 74 patients selected, 71 agreed to participate in the study. In all 
patients diagnosis had been made by enlarged thyroid glands, elevated TPO Abs and/or Tg 
Abs as well as typical hypoechogenicity of the thyroid in high-resolution sonography. 
Serum levels of TSH, free thyroxin (fT4) and lipid profile [total cholesterol (TC), triglyceride 
(TGs), LDL- and HDL- cholesterol (LDL-C and HDL-C)] were estimated. Patients were 
divided into tree subgroups according to the thyroid function. Group I (n=19) involved 
subjects with normal thyroid function (TSH and fT4 within the normal range). Group II 
(n=20) included patients with hypothyroidism (high levels of TSH and low or normal serum 
levels of fT4). In group III (n=32) were enrolled subjects with hypothyroidism treated with 
Levothyroxine (LT4) in a dosage to maintain TSH and fT4 within the normal range. The 
medication of Levothyroxine was given in the fasting state, mean Levothyroxine doses were 
83.227.7 g daily (range: 50-200 g). 
Blood samples, obtained from 30 healthy individuals (4 males, 26 females, of mean age 43.8 
 12.3 years) who had no family history of autoimmune disease were used as controls. To 
eliminate the factors, that might affect parameters of oxidative stress, we excluded from 
Hashimoto’s thyroiditis patients and healthy controls, all smoking and alcohol drinking 
subjects, as well as individuals suffering from acute or chronic diseases. Informed consent 
was obtained from all participants in the study according to the ethical guidelines of the 
Helsinki Declaration. Fasting samples of venous blood were collected in the morning 
between 8.00 and 10.00 h. FT4 was measured by competitive immunoassay on the ACS180 
(Chiron Diagnostics USA). TSH was measured by a third generation two-site 
chemiluminometric assay on the ACS180. The reference range was 11.5-22.7 pmol/l for FT4 
and 0.35-5.5 IU/ml for TSH. Serum TC, HDL-C and TG concentrations were determined 
enzymatically in the routine laboratory by automated procedures (Roche). Serum LDL-C 
was calculated according to the Friedewald formula. 
Blood for determining the parameters of oxidative stress was collected in tubes containing 
ethylendiamine-tetraacetic acid (EDTA), centrifuged at 3000 rpm for 15 min and plasma was 
carefully separated. The erythrocyte pellets were washed three times with saline, and 0.5 ml 
of the cell suspension was diluted with 2 ml cold water to lyse the erythrocytes. To 0.2 ml 
lysat 1.8 ml water and ethanol/chloroform (3:5/v:v) were then added to precipitate 
hemoglobin. The tubes were shaken vigorously for 5 min. The supernatant was used for 
determination of enzyme activity.  
Total amount of lipid peroxidation products in the plasma of healthy volunteers and 
patients was estimated using the thiobarbituric acid (TBA) method, which measures the 
malondialdehyde (MDA) reactive products (Plaser et al., 1996). The results were expressed 
as M/l. Superoxide dismutase activity was determined as described by Sun et al., (Sun at 
al., 1988) with minor modifications. The results were expressed as U/gHb. Catalase activity 
in the erythrocyte lysats was assessed by the method described by Beers and Sizer (Beers & 
Sizer, 1952). The hemoglobin concentration of lysate was determined by the 
cyanmethemoglobin method (Mahoney et al., 1993). Glutathione peroxidase activity was 
measured by the method of Paglia et al (Paglia et al., 1967). Activity was given in units per g 
hemoglobin (U/g Hb). 
www.intechopen.com
 
A New Look at Hypothyroidism 
 
110 
Characteristics 
 
Group I  
 
Group II  Group III 
N N=19 
 
N=20 N=32 
Age (yr) 
 
46.114.9 41.814.5 48.410.7 
Sex F/M 
 
17/2 1/19 1/31 
BMI (kg/m2) 
 
27.63.2 28.45.9 28.85.8 
TSH basal (mIU/l) 
 
2.31.2 * 16.04.9 * # 3.94.8 # 
Free T4 (pmol/l) 
 
14.81.3 * 10.62.4 *# 162.4# 
Total cholesterol 
(mmol/l) 
 
6.01.1 6.31.3 5.60.8 
LDL-C (mmol/l) 
 
4.01.0 3.81.1 3.50.6 
HDL-C (mmol/l) 
 
1.40.5 1.60.3 1.40.3 
Triglycerides (mmol/l) 
 
1.60.6 1.60.9 1.41.1 
* p<0.05; # p<0.05 are statistically significant (Student’s t-test) 
Table 4. Baseline characteristics of Hashimoto’s thyroiditis patients - euthyroid group 
(Group I), hypothyroid group (Group II) and group of patients treated with Levothyroxine 
(Group III). The results are expressed as mean  S.D 
Statistical analysis was carried out using the Statistica 5.5 for Windows. The results were 
reported as means  SD (SE). Student’s t-test was used to determine whether differences 
between means were significant. Correlations between the different parameters were 
calculated by linear regression analysis. P  0.05 was considered statistically significant. 
Clinical and biochemical data of subgroups of Hashimoto’s thyroiditis patients are 
presented in Table 4. In hypothyroid Hashimoto’s patients cholesterol levels tended to be 
higher compared to euthyroid patients and patients treated with LT4. Results of studied 
parameters of oxidative stress in controls and Hashimoto’s patients are listed in Table 5. 
There were no significant changes of plasma levels of MDA between the groups of patients 
(group I - 1.680.08; group II - 1.900.13; group III – 1.710.07 mol/l; respectively) as well 
as between the patients and the controls (1.700.06 mol/l). Only plasma levels of MDA in 
hypothyroid Hashimoto’s patients (group II) tended to be higher. No significant differences 
in SOD activity in erythrocytes were observed between the groups of patients (group I - 
2377262; group II - 2602190; group III – 2308267 U/gHb; respectively) and the controls 
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(2597156 U/gHb. Our results showed that CAT activity was significantly lower in 
hypothyroid patients (group II) in comparison with controls (160163875 vs 268552272 
U/gHb, p=0.01) and in coparison with subjects treated with LT4 (group III) (160163875 vs 
292503939 U/gHb, p=0.02). Erythrocyte CAT activity of patients in euthyroid stage (group 
I) was also found significantly decreased compared to the controls (187333188 vs 
268552272 U/gHb, p=0.04). Activity of GPX in erythrocytes in hypothyroidism (group II) 
was higher compared to control group (8.30.6 vs. 6.40.4 U/gHb, p=0.02). In euthyroid 
Hashimoto’s patients (group I) and in patients treated with LT4 (group III), the activity of 
GPX was found significantly decreased in comparison with hypothyroid patients (5.71.1 vs 
8.30.6 and 5.21.1 vs 8.30.6 U/gHb; p=0.05, p=0.047, respectively). GPX activity in both 
groups I and III, also tended to be lower in comparison with controls, but not significantly 
(Fig. 5).   
  Groups 
 
Parameters 
 
Controls 
 
Group I 
 
Group II  
 
Group III 
N 30 19 20 32 
MDA 
(mol/l) 
1.70  0.06 1.68  0.08  1.90  0.13 1.71  0.07  
SOD   
(U/gHb) 
2597  156  2377   262 2602  190 2308  267 
CAT   
(U/gHb) 
26855  2272 a b 18773   3188 b 16016  3875 a c 29250  3939c 
GPX 
(U/gHb) 
6.4  0.4 a 5.70   1.1 c 8.3  0.6 a b c 5.2  1.1 b  
The results are expressed as mean  S.E.  
Student’s t-test was used to compute the statistical significance of values  
aCAT p<0.05; bCAT p <0.05; cCATp < 0.05 
aGPX: p<0.05; bGPX p <0.05; cGPX p < 0.05 
Table 5. Levels of lipid peroxidation products – malondialdehyde (MDA) (mol/l) in the 
plasma and the activities of antioxidative enzymes superoxide dismutase (SOD) (U/gHb), 
catalase (CAT) (U/gHb), and glutathione peroxidase (GPX) (U/gHb) in erythrocytes of control 
group and Hashimoto’s thyroiditis patients – euthyroid group (Group I), hypothyroid group 
(Group II) and group of patients treated with Levothyroxine ( Group III).  
Significant negative linear correlation was found between activities of GPX and CAT in 
control group (r=- 0.57, p<0.05). However, no correlation was noted between activities of 
GPX and CAT in patient’s groups. Significant negative correlation was also observed 
between serum levels of TSH and CAT activity (r= -0.40, p<0.05) in both groups euthyroid 
(group I) and hypothyroid (group II) Hashimoto’s patients. 
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Fig. 5. Comparison of MDA levels in plasma and the activities of antioxidative enzymes 
superoxide dismutase (SOD) (U/gHb), catalase (CAT) (U/gHb), and glutathione peroxidase 
(GPX) (U/gHb) in erythrocytes of control group and Hashimoto’s thyroiditis patients – 
euthyroid group (I), hypothyroid group (II) and group of patients treated with 
Levothyroxine (III). The results are expressed as mean  S.E. 
The thyroid function is normal in a great number of patients with Hashimoto’s thyroiditis.  
Some of them, however, may progress to hypothyroidism over time. Although the highest 
titers of TPO antibodies are found in hypothyroid patients with Hashimoto’s thyroiditis, they 
can also be found in euthyroid patients, that is, the correlation of titers with thyroid functional 
status is contradictory (Amino et al., 1976, Aksoy et al., 2005; Ito et al., 2006). Pathogenitic role 
of TPO Abs is not clearly established, but they are recognized as marker of aitoimmune 
thyroid diseases and the presence of TPO Abs indicates that, the processes of thyroid 
destruction started many years, before establishment of thyroid hypofunction (Kraiem, 1998). 
Thyroid cells undergoing apoptosis occur with high level of frequency in thyroids from 
patients with Hashimoto’s thyroiditis (Kotani et al., 1995; Okayasu et al., 1995; Tanimoto et al., 
1995). Many of the apoptotic cells in these glands are detected in areas of disrupted follicles in 
proximity to infiltrating lymphoid cells (Kotani et al., 1995; Hammond et al., 1997). This 
suggests that the thyroid destruction in this disease occurs through thyroid cell apoptosis.  
In hypothyroid Hashimoto’s patients both the level of MDA tended to be higher as well as 
the cholesterol levels compared to euthyroid patients and patients treated with LT4. This 
might lead to the development and progression of atherosclerosis and possibly contribute to 
enhanced atherosclerosis risk in this group. 
Our data showed a lack of significant changes in activities of SOD in all groups of 
Hashimoto’s patients compared to controls, but in contrast, the results concerninig GPX and 
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CAT activities differed significantly in studied groups. At high concentrations ROS have 
been reported to induce oxidative damage to membrane lipids, proteins and DNA, and that 
might result in cell death by necrosis or apoptosis (Gamaley & Klyubin, 1999; Hampton & 
Orrenius, 1997). Both GPX and CAT are major defense against harmful side effect of ROS in 
cells and in cultured thyrocytes both have a high capacity to degrade exogenious H2O2 
(Björkman & Ekholm, 1995). Specifically, the observations indicate that GPX is involved in 
the degradation of fairly low H2O2 levels (100 mol/l) whereas CAT is required to degrade 
H2O2 at mmol/l concentrations. In thyroid tissue GPX is active in the cytosol and 
conceivably degrade H2O2 produced at the apical plasma membrane as soon as it enters the 
cell. CAT on the other hand, is mainly enclosed in the peroxisomes and therefore not 
directly accessible at the side of H2O2 production. It is thus possible that the impaired GPX 
and CAT activities may lead to H2O2-induced apoptosis to thyroid cells in Hashimoto’s 
thyroiditis patients.   
Our study clearly demonstrates lower activities on both enzymes – CAT and GPX in 
euthyroid Hashimoto’s patients. In hypothyroid stage, GPX production increased probably 
through hyperstimulation of TSH receptor by TSH (Beckett & Arthur, 2005), but CAT 
activity remained reduced. Significant negative linear correlation was found between 
activities of GPX and CAT in control group, but no correlation was noted between activities 
of GPX and CAT in patient’s groups. In in vitro study Demelash et al. found that impaired 
capacity of GPX to degrade H2O2 in cultured thyroid pig cells aggravates the apoptic 
response (Demelash et al., 2004). This data and our results suggest the possibility that 
reduced GPX and CAT activities in euthyroid Hashimoto’s patients might participate in the 
initiation of the autoimmune process and might lead to H2O2-induced damage of thyroid 
cells related to cytosolic oxidative stress. The compensatory increased activity of GPX in 
hypothyroid stage of disease is not sufficient to protect the thyrocytes from harmful effects 
of excess H2O2. 
After restoring euthyroidism with LT4 medication MDA reached levels close to control group 
and CAT activity increased while GPX again tended to be lower. Under in vitro conditions 
thyroid hormones triidothyronine and thyroxine revealed the capacity to scavenge free 
radicals (Aziol et al., 2001). Erdamar et al. demonstrate an increased generation of reactive 
oxygen species and impairment of the antioxidant system in patients with hypothyroidism 
due to Hashimoto’s thyroiditis.; after restoring euthyroidism the values normalize (Erdamar et 
al.,2008). These findings indicate that thyroid hormones have a strong impact on oxidative 
stress and the antioxidant system. Our results demonstrate that treatment with LT4 in 
Hashimoto’s patients is useful, but insufficient to normalize all of parameters of oxidative 
stress. Aksoy et al. found significant decrease of TPO Abs and Tg Abs in euthyroid 
Hashimoto’s thyroiditis after prophylactic thyroid hormone replacement, but increase of CD8+ 
cell counts (Askoy et al., 2005). We may suppose that thyroid hormones in small doses may be 
used in some groups of euthyroid Hashimoto’s thyroiditis patients e.g. with subtle brain 
dysfunction or depression in view of their antioxidant properties. 
Selenium supplementation produced a significant decline in TPO Abs in hypothyroid 
Hashimoto’s patients (Gärtner et al., 2002; Duntas et al., 2003). In experimental study 
selenium increases cellular levels of GPX and CAT (Alvarado al., 2006). Our results indicate 
a deficiency of cellular antioxidative defense in Hashimoto’s thyroiditis patients in all stages 
of disease and the observed imbalance may be connected to the processes of thyroid cell 
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apoptosis. We may speculate that the supplementation with antioxidants including 
selenium, from an early stage of the disease, in addition to thyroid hormone replacement 
may have positive benefit in Hashimoto’s disease’s treatment.  
4. Conclusion  
In the past decade, significant progress has been made in our understanding of the genetic 
and environmental triggers contributing to HD. Meanwhile, HT is also a heterogeneous 
disorder exhibiting various clinicopathological presentations and outcomes. The thyroid 
autoantibodies, cytokines and antioxidative cellular enzymes are involved in the severity of 
Hashimoto’s thyroiditis and they may be influenced by ethnic differences and 
environmental factors. The determination of cytokines in peripheral blood provides 
information about the involvement of cytokine network in the severity of Hashimotos’s 
thyroiditis and variations in their concentrations may be connected with different clinical 
course of disease in patients. Our results have shown that IL-12 and IL-18 play an influential 
role in inflammatory response; in the induction and perpetuation of chronic inflammation in 
autoimmune thyroiditis. These findigs suggest that antagonists to these cytokines may have 
a potential therapeutic role against Hashimoto’s thyroiditis. We found a deficiency of 
cellular antioxidative defense in Hashimoto’s thyroiditis patients in all stages of disease and 
the observed imbalance may be connected to the processes of thyroid cell apoptosis. 
Levothyroxine treatment and the supplementation with antioxidants mainly with selenium 
restore the imbalance, but what is needed is a new type of antioxidant, such as a CAT/GPX 
mimetic, that works continuously and may be a powerful new approach for correction of 
Hashimoto’s thyroiditis-induced oxidative stress. Further studies are necessary to establish 
the exact mechanism of autoantibodies, cytokines and antioxidant enzymes interaction 
influencing the severity of Hashimoto’s thyroiditis.  
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